Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 18, 2024
Event: Entry into a Material Definitive Agreement involving a private placement of securities and a related promissory note to fund operations and support a planned business combination with SEP Acquisition Corp. ("SEPA").
Key Financial Metrics and Capital Structure
Total Proceeds Received: $1.8 million on June 18, 2024.
- Convertible Notes: $1.3 million aggregate principal amount issued to purchasers.
- Promissory Note: $0.5 million issued to Manchester Explorer, L.P.
Debt Terms:
- Interest Rate: 15% per annum on both the Convertible Notes and the Promissory Note.
- Conversion Price: $0.04 per share (subject to adjustment, with a floor of $0.01).
- Maturity: The Promissory Note matures on December 18, 2024. The Convertible Notes are subject to acceleration, conversion, or redemption.
Warrants Issued:
- First Warrants: 32.5 million shares at an exercise price of $0.067 per share.
- Second Warrants: 32.5 million shares at an exercise price of $0.04 per share.
- Term: Five years.
Liquidity and Subordination: The rights of purchasers under the Convertible Notes are subordinate to the rights of NH Expansion Credit Fund Holdings LP ("North Haven Expansion").
Material Changes and Agreements
The filing details a significant capital raise and restructuring of obligations:
- Private Placement: The Company sold future advance convertible promissory notes and warrants in a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
- Related Party Transaction: The $0.5 million Promissory Note was issued to Manchester Explorer, L.P., a beneficial owner of more than 5% of the Company's common stock. Morgan Frank, the Company's Chairman and CEO, serves as a portfolio manager and consultant for Manchester.
- Waivers: Purchasers waived certain obligations through December 31, 2024, including the requirement for a reverse stock split and the immediate registration of shares underlying the Notes and Warrants.
- Registration Rights: The Company agreed to file a registration statement within 60 days of the closing date to register the resale of shares issuable upon conversion or exercise.
Outlook, Risks, and Management Commentary
Planned Business Combination: The financing supports a planned merger with SEP Acquisition Corp. (SEPA). Purchasers agreed to exchange Notes and Warrants for common stock immediately prior to the closing of this transaction or upon a reverse stock split.
Exchange Terms for Merger:
- Notes will be exchanged for common stock at a ratio of $0.04 per share (covering principal and accrued interest).
- First Warrants will be exchanged for 0.85 shares of common stock per warrant share.
- Second Warrants will be exchanged for 0.9 shares of common stock per warrant share.
Risks and Contingencies:
- Merger Conditions: The transaction with SEPA requires SEPA to have at least $12.0 million at closing from non-redeemed stock and private placement proceeds.
- Regulatory and Listing: Risks include delays in regulatory approvals and the inability to maintain a Nasdaq listing post-transaction.
- Forward-Looking Statements: The Company cautions that actual results may differ materially from expectations regarding the timing and consummation of the merger.
Investor Verification Checklist
- Verify the status of the planned business combination with SEP Acquisition Corp. and whether the $12.0 million closing condition has been met.
- Review the full text of the Subordination Agreement to understand the priority of claims relative to North Haven Expansion.
- Confirm the filing status of the Registration Statement required within 60 days of June 18, 2024.
- Monitor the Company's ability to service the 15% interest on the $1.8 million debt prior to the December 18, 2024 maturity of the Promissory Note or the closing of the merger.
- Assess the potential dilution impact of the 65 million warrant shares and the conversion of the $1.3 million notes at the $0.04 conversion price.